A Phase 4 interventional study of Fluticasone propionate and Placebo in Rhinitis, Allergic, Perennial and Allergic Rhinitis, sponsored by GlaxoSmithKline. Completed at 1 site in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-09-24.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial — 1 open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Perennial.
Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, this one is the 18th largest by enrollment, is one of 4 that started in 2007, is one of 7 in phase 4, and was the 16th registered.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
Browse Rhinitis, Allergic, Perennial studies →1 of the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial is open now, in 1 country. Recruiting first, the newest first:
HALEON · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Median enrollment 288 across the 21 interventional studies. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 28 finished, 13 (46%) have results posted.
Among the 28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2007, is one of 7 in phase 4, and was the 22nd registered.
GlaxoSmithKline’s Rhinitis, Allergic, Perennial studies by the year they started, since 2005.
1 of the studies testing fluticasone in Rhinitis, Allergic, Perennial that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07817134HALEONA Study to Visualize Multi-Symptom Allergy in Adults With Seasonal Allergic Rhinitis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 28 in Rhinitis, Allergic, Perennial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber in subjects with allergic rhinitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female is eligible to enter and participate in the study if she is of:
Child bearing potential, has a negative pregnancy test (urine) at entry, and agrees to one of the following acceptable methods when used consistently and correctly (i.e., in accordance with the approved product label and the instructions of a physician for the duration of the study - screening visit to follow-up contact):
Pack years = Number of cigarettes per day x Number of years smoked 20
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Fluticasone propionate
Drug: Fluticasone propionate
Drug: Fluticasone propionate
Drug: Fluticasone propionate
Corticosteriod, with anti-inflammatory effects
Placebo comparator
Weighted Mean Total Nasal Symptom Score (TNSS) at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge [PSC]) in the Vienna Challenge Chamber (VCC)
The TNSS (score of 0-12), defined as the sum of the symptom scores for nasal obstruction, rhinorrhea, nasal itch, and sneeze (each scored on 0-3 scale \[0=none, 1=mild, 2=moderate, 3=severe\]) was measured at pre-challenge, and then every 15 minutes from 0.25 to 4 hours PSC. In the VCC, aerosolized allergen is administered in a sealed chamber to evaluate the efficacy of antihistamines/other treatments. Weighted mean TNSS was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
Time frame: Day 8 of each study period (Periods 1-4); up to Day 158
Weighted Mean Nasal Airflow at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
Allergic rhinitis decreases the passage of air through the nose (nasal airflow) by increasing the nasal airway resistance. Rhinomanometry is used as an objective measurement of airway resistance. Nasal airflow was measured using active anterior rhinomanometry at pre-challenge, and then every 30 minutes from 0.5 to 4 hours post start of VCC. Weighted mean nasal airflow was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
Time frame: Day 8 of each study period (Periods 1-4); up to Day 158
Weighted Mean Nasal Secretion at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
Nasal secretion was measured by weighing tissues used by participants. Wet tissue weight assessments were made pre-challenge, and then every 30 minutes from 0.5 to 4 hours post start of challenge chamber throughout the study. Weighted mean nasal secretion was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
Time frame: Day 8 of each study period (Periods 1-4); up to Day 158
Weighted Mean Eye Symptom Score at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
The eye symptom score (total score of 0 \[none\] to 9 \[severe\]) was calculated as the sum of the symptom scores for watery eyes, itchy eyes, and red eyes, each of which was scored on a categorical scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), and was measured at pre-challenge, and then every 15 minutes from 0.25 to 4 hours post-start of challenge chamber. Weighted mean eye symptom score was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
Time frame: Day 8 of each study period (Periods 1-4); up to Day 158
Weighted Mean Global Symptom Score (GSS) at 5 Hours Post-dose (1-4 Hours Post-start of Challenge)
GSS (total score=0-30) is calculated as the sum of sneeze, nasal itch, rhinorrhea, nasal obstruction, cough, itchy throat, itchy ears, watery eyes, itchy eyes, and red eyes SSs, each of which was scored on a categorical scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), as was measured at pre-challenge, and then every 15 mins from 0.25 to 4 hours post-start of challenge chamber. Weighted mean global symptom score was evaluated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
Time frame: Day 8 of each study period (Periods 1-4); up to Day 158
Glucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: CCL2
AROS Applied Biotechnology (AB) analyzed the nasal epithelial scrapings of participants and generated TaqMan (type of chemistry developed by AB to detect polymerase chain reaction \[PCR\] products) messenger ribonucleic acid (mRNA) biomarker expression data for CCL2, a steroid-responsive gene. Preliminary analysis of the mRNA abundance data was performed by Discovery Statistics. mRNA abundance data were normalized to the scores of GAPDH and 18S housekeeping genes. B-actin was not used. CCL2 data are presented by period to show the treatment-by-period interaction. ng, nanograms.
Time frame: Day 1 (pre-dose) and Day 8 of each study period (Periods 1-4); up to Day 158
Glucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: 18S, B-actin, DUSP_1_T1, FKBP5, GAPDH, GILZ, PLAU, PTGS2, and RGS2
AROS Applied Biotechnology (AB) analyzed the nasal epithelial scrapings of participants and generated TaqMan (type of chemistry developed by AB to detect polymerase chain reaction \[PCR\] products) messenger ribonucleic acid (mRNA) biomarker expression data for 7 steroid-responsive genes (DUSP_1_TI, FKBP5, GILZ, PLAU, CCL2, PTGS2, and RGS2) and 3 housekeeping reference genes (GAPDH, 18S, and b-actin). Preliminary analysis of the mRNA abundance data was performed by Discovery Statistics. mRNA abundance data were normalized to the scores of GAPDH and 18S housekeeping genes. B-actin was not used.
Time frame: Day 1 (pre-dose) and Day 8 of each study period (Periods 1-4); up to Day 158
| Milestone | Placebo/FP 25, 50, 100, 200 µg |
|---|---|
| Started | 59 |
| Completed | 57 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
The TNSS (score of 0-12), defined as the sum of the symptom scores for nasal obstruction, rhinorrhea, nasal itch, and sneeze (each scored on 0-3 scale \[0=none, 1=mild, 2=moderate, 3=severe\]) was measured at pre-challenge, and then every 15 minutes from 0.25 to 4 hours PSC. In the VCC, aerosolized allergen is administered in a sealed chamber to evaluate the efficacy of antihistamines/other treatments. Weighted mean TNSS was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
| scores on a scale | Placebo | 25 µg FP | 50 µg FP | 100 µg FP | 200 µg FP |
|---|---|---|---|---|---|
| Weighted Mean Total Nasal Symptom Score (TNSS) at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge [PSC]) in the Vienna Challenge Chamber (VCC) | 7.17 ± 2.912 | 5.54 ± 2.437 | 5.66 ± 2.280 | 5.29 ± 2.218 | 4.77 ± 2.433 |
Allergic rhinitis decreases the passage of air through the nose (nasal airflow) by increasing the nasal airway resistance. Rhinomanometry is used as an objective measurement of airway resistance. Nasal airflow was measured using active anterior rhinomanometry at pre-challenge, and then every 30 minutes from 0.5 to 4 hours post start of VCC. Weighted mean nasal airflow was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
| Milliliters per second (mL/s) | Placebo | 25 µg FP | 50 µg FP | 100 µg FP | 200 µg FP |
|---|---|---|---|---|---|
| Weighted Mean Nasal Airflow at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge) | 335.20 ± 145.373 | 368.66 ± 144.230 | 375.94 ± 142.105 | 362.59 ± 142.216 | 411.65 ± 160.148 |
Nasal secretion was measured by weighing tissues used by participants. Wet tissue weight assessments were made pre-challenge, and then every 30 minutes from 0.5 to 4 hours post start of challenge chamber throughout the study. Weighted mean nasal secretion was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
| grams (g) | Placebo | 25 µg FP | 50 µg FP | 100 µg FP | 200 µg FP |
|---|---|---|---|---|---|
| Weighted Mean Nasal Secretion at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge) | 2.43 ± 2.203 | 1.63 ± 1.893 | 1.43 ± 1.458 | 1.26 ± 1.550 | 1.02 ± 1.271 |
The eye symptom score (total score of 0 \[none\] to 9 \[severe\]) was calculated as the sum of the symptom scores for watery eyes, itchy eyes, and red eyes, each of which was scored on a categorical scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), and was measured at pre-challenge, and then every 15 minutes from 0.25 to 4 hours post-start of challenge chamber. Weighted mean eye symptom score was calculated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
| scores on a scale | Placebo | 25 µg FP | 50 µg FP | 100 µg FP | 200 µg FP |
|---|---|---|---|---|---|
| Weighted Mean Eye Symptom Score at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge) | 2.35 ± 2.240 | 1.52 ± 1.678 | 1.44 ± 1.711 | 1.93 ± 1.726 | 1.41 ± 1.491 |
GSS (total score=0-30) is calculated as the sum of sneeze, nasal itch, rhinorrhea, nasal obstruction, cough, itchy throat, itchy ears, watery eyes, itchy eyes, and red eyes SSs, each of which was scored on a categorical scale from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), as was measured at pre-challenge, and then every 15 mins from 0.25 to 4 hours post-start of challenge chamber. Weighted mean global symptom score was evaluated by dividing the value of the area under the response time curve between 1 and 4 hours (calculated by trapezoidal rule) by the time interval of available data.
| scores on a scale | Placebo | 25 µg FP | 50 µg FP | 100 µg FP | 200 µg FP |
|---|---|---|---|---|---|
| Weighted Mean Global Symptom Score (GSS) at 5 Hours Post-dose (1-4 Hours Post-start of Challenge) | 11.14 ± 5.407 | 8.17 ± 4.302 | 8.24 ± 4.231 | 8.69 ± 4.346 | 7.13 ± 3.487 |
AROS Applied Biotechnology (AB) analyzed the nasal epithelial scrapings of participants and generated TaqMan (type of chemistry developed by AB to detect polymerase chain reaction \[PCR\] products) messenger ribonucleic acid (mRNA) biomarker expression data for CCL2, a steroid-responsive gene. Preliminary analysis of the mRNA abundance data was performed by Discovery Statistics. mRNA abundance data were normalized to the scores of GAPDH and 18S housekeeping genes. B-actin was not used. CCL2 data are presented by period to show the treatment-by-period interaction. ng, nanograms.
| Copies of RNA detected per 50ng of total | Placebo | 25 µg FP | 50 µg FP | 100 µg FP | 200 µg FP |
|---|---|---|---|---|---|
| Period 1, n=12, 12, 12, 11, 11 | 12396.08096 (5928.406 to 25919.75529) | 1377.248941 (678.7116 to 2794.728503) | 1231.251053 (605.7205 to 2502.769902) | 3340.460181 (1599.611 to 6975.866146) | 3377.403394 (1625.327 to 7018.188693) |
| Period 2, n=11, 11, 11, 12, 11 | 4206.320679 (1991.881 to 8882.624596) | 2192.232108 (1015.906 to 4730.634081) | 1765.627412 (849.2589 to 3670.781431) | 2342.488506 (1127.738 to 4865.715164) | 2821.11204 (1355.137 to 5872.967075) |
| Period 3, n=11, 11, 11, 12, 12 | 4135.167835 (1987.132 to 8605.171059) | 3612.444351 (1730.839 to 7539.553498) | 2184.76185 (1051.383 to 4539.910315) | 1229.316666 (609.3241 to 2480.157112) | 2505.03196 (1234.885 to 5081.594294) |
| Period 4, n=12, 11, 11, 11, 12 | 10111.38124 (5019.348 to 20369.18487) | 3523.276415 (1674.529 to 7413.114228) | 2615.352938 (1249.52 to 5474.157686) | 1917.918706 (889.5355 to 4135.205377) | 1071.598621 (515.8547 to 2226.060108) |
AROS Applied Biotechnology (AB) analyzed the nasal epithelial scrapings of participants and generated TaqMan (type of chemistry developed by AB to detect polymerase chain reaction \[PCR\] products) messenger ribonucleic acid (mRNA) biomarker expression data for 7 steroid-responsive genes (DUSP_1_TI, FKBP5, GILZ, PLAU, CCL2, PTGS2, and RGS2) and 3 housekeeping reference genes (GAPDH, 18S, and b-actin). Preliminary analysis of the mRNA abundance data was performed by Discovery Statistics. mRNA abundance data were normalized to the scores of GAPDH and 18S housekeeping genes. B-actin was not used.
| RNA copies detected per 50 ng total RNA | Placebo | 25 µg FP | 50 µg FP | 100 µg FP | 200 µg FP |
|---|---|---|---|---|---|
| 18S | 6439292568 (5953473924 to 6964755253) | 6109603485 (5653823536 to 6602125890) | 5822423622 (5388052053 to 6291813164) | 6218835383 (5759650434 to 6714628599) | 6222906532 (5758553637 to 6724703483) |
| B-actin | 1978137.142 (1761487.822 to 2221432.646) | 1481307.983 (1316851.063 to 1666303.352) | 1629006.342 (1448708.283 to 1831743.28) | 1630387.679 (1451329.134 to 1831537.671) | 1543748.32 (1374839.809 to 1733408.402) |
| DUSP_1_T1 | 107004.8077 (87973.18828 to 130153.6195) | 104633.517 (85852.10596 to 127523.6379) | 107031.4158 (88881.02888 to 128888.2916) | 118158.2593 (97226.90284 to 143595.7933) | 113323.9632 (91653.05005 to 140118.8573) |
| FKBP5 | 28739.3975 (24256.97193 to 34050.12675) | 155791.0745 (131185.2632 to 185012.0837) | 174963.5715 (147311.3952 to 207806.4043) | 177935.1307 (150181.7514 to 210817.2961) | 151362.3934 (127521.6515 to 179660.2684) |
| GAPDH | 5776051.293 (5326118.123 to 6263993.356) | 6143058.472 (5659602.91 to 6667811.859) | 6451580.253 (5943884.286 to 7002640.993) | 6008446.351 (5540570.46 to 6515832.227) | 5972472.493 (5507396.953 to 6476821.624) |
| GILZ | 13601.9459 (11833.92763 to 15634.1105) | 26629.75763 (23090.34785 to 30711.70672) | 29304.22353 (25490.27435 to 33688.8299) | 28832.53255 (25122.37093 to 33090.62412) | 27304.24721 (23763.4653 to 31372.60943) |
| PLAU | 26364.53138 (22020.16973 to 31565.99261) | 18550.2079 (15417.62826 to 22319.27033) | 18810.56868 (15681.73421 to 22563.67116) | 20918.214 (17454.94721 to 25068.63365) | 21692.66346 (18117.03777 to 25973.98394) |
| PTGS2 | 42479.35246 (34135.93482 to 52862.04685) | 31120.01509 (24904.20116 to 38887.22762) | 35049.7556 (28101.49486 to 43716.01489) | 38443.85612 (30827.02769 to 47942.67187) | 33657.71928 (27031.4341 to 41908.32284) |
| RGS2 | 55084.11432 (45323.01163 to 66947.44108) | 45255.7763 (37098.26279 to 55207.04028) | 54186.44212 (44490.27052 to 65995.78907) | 50507.30739 (41546.43595 to 61400.88895) | 50373.91657 (41440.13318 to 61233.67074) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/46 (0%) | 4/46 (8.7%) |
| 25 µg FP | — | 0/46 (0%) | 6/46 (13%) |
| 50 µg FP | — | 0/46 (0%) | 3/46 (6.5%) |
| 100 µg FP | — | 0/46 (0%) | 2/46 (4.3%) |
| 200 µg FP | — | 0/47 (0%) | 1/47 (2.1%) |
| Event | Placebo | 25 µg FP | 50 µg FP | 100 µg FP | 200 µg FP |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/46 | 3/46 | 1/46 | 0/46 | 0/47 |
| NasopharygitisInfections and infestations | 1/46 | 2/46 | 0/46 | 0/46 | 1/47 |
| Bronchitis bacterialInfections and infestations | 0/46 | 1/46 | 0/46 | 0/46 | 0/47 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/46 | 0/46 | 1/46 | 1/46 | 0/47 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/46 | 0/46 | 0/46 | 1/46 | 0/47 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 0/46 | 0/46 | 1/46 | 0/46 | 0/47 |
| Abdominal pain upperGastrointestinal disorders | 0/46 | 1/46 | 0/46 | 0/46 | 0/47 |
| NauseaGastrointestinal disorders | 0/46 | 0/46 | 1/46 | 0/46 | 0/47 |
| VomitingGastrointestinal disorders | 0/46 | 0/46 | 1/46 | 0/46 | 0/47 |
| Ear painEar and labyrinth disorders | 0/46 | 0/46 | 1/46 | 0/46 | 0/47 |
| Age Continuous(Years) | Placebo/FP 25, 50, 100, 200 µg |
|---|---|
| Mean | 27.2 ± 5.30 |
| Sex: Female, Male(Participants) | Placebo/FP 25, 50, 100, 200 µg |
|---|---|
| Female | 30 |
| Male | 29 |
| Race/Ethnicity, Customized(participants) | Placebo/FP 25, 50, 100, 200 µg |
|---|---|
| Japanese/East Asian Heritage (EAH)/South EAH | 1 |
| White | 58 |
The record gives a start of Oct 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Rhinitis, Allergic, Perennial →